In the daylong meeting June 28, the independent panel didn’t direct vaccine manufacturers on which omicron strains to target or whether to focus on a bivalent (containing omicron and a prototype) or a monovalent (containing omicron) vaccine. The FDA now points to the two subvariants and a bivalent vaccine containing a “BA.4/5 spike protein component.”
“As we move into the fall and winter, it is critical that we have safe and effective vaccine boosters that can provide protection against circulating and emerging variants to prevent the most severe consequences of COVID-19,” Peter Marks, MD, PhD, the director of the Center for Biologics Evaluation and Research, said in a statement.
Subvariants BA.4 and BA.5 account for 52.3 percent of COVID-19 infections in the U.S., according to recent CDC estimates.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
